Studies have also suggested that inhibition of HSP90 expression can down-regulate expression of EGFR mutants (18–20) and become potential second-line treatment for non-small-cell lung cancers (21–23). The gene discussed is HSP90AA1; the disease is non-small cell lung carcinoma.